Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

The molecular origin and taxonomy of mucinous ovarian carcinoma.

Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Anglesio MS, Au-Yeung G, Böhm M, Bowtell DDL, Brand A, Chenevix-Trench G, Christie M, Chiew YE, Churchman M, DeFazio A, Demeo R, Dudley R, Fairweather N, Fedele CG, Fereday S, Fox SB, Gilks CB, Gourley C, Hacker NF, Hadley AM, Hendley J, Ho GY, Hughes S, Hunstman DG, Hunter SM, Jobling TW, Kalli KR, Kaufmann SH, Kennedy CJ, Köbel M, Le Page C, Li J, Lupat R, McNally OM, McAlpine JN, Mes-Masson AM, Mileshkin L, Provencher DM, Pyman J, Rahimi K, Rowley SM, Salazar C, Samimi G, Saunders H, Semple T, Sharma R, Sharpe AJ, Stephens AN, Thio N, Torres MC, Traficante N, Xing Z, Zethoven M, Antill YC, Scott CL, Campbell IG, Gorringe KL.

Nat Commun. 2019 Sep 2;10(1):3935. doi: 10.1038/s41467-019-11862-x.

2.

Combined tumor sequencing and case/control analyses of RAD51C in breast cancer.

Li N, McInerny S, Zethoven M, Cheasley D, Lim BWX, Rowley SM, Devereux L, Grewal N, Ahmadloo S, Byrne D, Lee JEA, Li J, Fox SB, John T, Antill Y, Gorringe KL, James PA, Campbell IG.

J Natl Cancer Inst. 2019 Apr 5. pii: djz045. doi: 10.1093/jnci/djz045. [Epub ahead of print]

PMID:
30949688
3.

Molecular comparison of interval and screen-detected breast cancers.

Cheasley D, Li N, Rowley SM, Elder K, Mann GB, Loi S, Savas P, Goode DL, Kader T, Zethoven M, Semple T, Fox SB, Pang JM, Byrne D, Devereux L, Nickson C, Procopio P, Lee G, Hughes S, Saunders H, Fujihara KM, Kuykhoven K, Connaughton J, James PA, Gorringe KL, Campbell IG.

J Pathol. 2019 Jun;248(2):243-252. doi: 10.1002/path.5251. Epub 2019 Mar 8.

PMID:
30746706
4.

Paraneoplastic Encephalopathy in a Patient With Metastatic Lung Cancer: A Case Study.

Rowley SM.

J Adv Pract Oncol. 2018 Mar;9(2):216-221. Epub 2018 Mar 1. Review.

5.

Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility.

Rowley SM, Mascarenhas L, Devereux L, Li N, Amarasinghe KC, Zethoven M, Lee JEA, Lewis A, Morgan JA, Limb S, Young MA, James PA, Trainer AH, Campbell IG.

Genet Med. 2019 Apr;21(4):913-922. doi: 10.1038/s41436-018-0277-0. Epub 2018 Sep 26.

PMID:
30254378
6.

Mutations in RECQL are not associated with breast cancer risk in an Australian population.

Li N, Rowley SM, Goode DL, Amarasinghe KC, McInerny S, Devereux L; LifePool Investigators, Wong-Brown MW, Lupat R, Lee JEA, Hughes S, Thompson ER, Zethoven M, Li J, Trainer AH, Gorringe KL, Scott RJ, James PA, Campbell IG.

Nat Genet. 2018 Oct;50(10):1346-1348. doi: 10.1038/s41588-018-0206-9. No abstract available.

PMID:
30224651
7.

Mutational Landscape of Ovarian Adult Granulosa Cell Tumors from Whole Exome and Targeted TERT Promoter Sequencing.

Alexiadis M, Rowley SM, Chu S, Leung DTH, Stewart CJR, Amarasinghe KC, Campbell IG, Fuller PJ.

Mol Cancer Res. 2019 Jan;17(1):177-185. doi: 10.1158/1541-7786.MCR-18-0359. Epub 2018 Aug 30.

PMID:
30166312
8.

Molecular analysis of PALB2-associated breast cancers.

Lee JEA, Li N, Rowley SM, Cheasley D, Zethoven M, McInerny S, Gorringe KL, James PA, Campbell IG.

J Pathol. 2018 May;245(1):53-60. doi: 10.1002/path.5055. Epub 2018 Mar 30.

PMID:
29431189
9.

Evaluating the breast cancer predisposition role of rare variants in genes associated with low-penetrance breast cancer risk SNPs.

Li N, Rowley SM, Thompson ER, McInerny S, Devereux L, Amarasinghe KC, Zethoven M, Lupat R, Goode D, Li J, Trainer AH, Gorringe KL, James PA, Campbell IG.

Breast Cancer Res. 2018 Jan 9;20(1):3. doi: 10.1186/s13058-017-0929-z.

10.

Erratum to: Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors.

Ryland GL, Hunter SM, Doyle MA, Caramia F, Li J, Rowley SM, Christie M, Allan PE, Stephens AN, Bowtell DD; Australian Ovarian Cancer Study Group, Campbell IG, Gorringe KL.

Genome Med. 2017 Jan 12;9(1):1. doi: 10.1186/s13073-016-0392-y. No abstract available.

11.

Copy number analysis by low coverage whole genome sequencing using ultra low-input DNA from formalin-fixed paraffin embedded tumor tissue.

Kader T, Goode DL, Wong SQ, Connaughton J, Rowley SM, Devereux L, Byrne D, Fox SB, Mir Arnau G, Tothill RW, Campbell IG, Gorringe KL.

Genome Med. 2016 Nov 15;8(1):121.

12.

Editor's Highlight: Development of an In vitro Assay Measuring Uterine-Specific Estrogenic Responses for Use in Chemical Safety Assessment.

Miller MM, Alyea RA, LeSommer C, Doheny DL, Rowley SM, Childs KM, Balbuena P, Ross SM, Dong J, Sun B, Andersen MA, Clewell RA.

Toxicol Sci. 2016 Nov;154(1):162-173. Epub 2016 Aug 7.

13.

Reevaluation of RINT1 as a breast cancer predisposition gene.

Li N, Thompson ER, Rowley SM, McInerny S, Devereux L, Goode D, Investigators L, Wong-Brown MW, Scott RJ, Trainer AH, Gorringe KL, James PA, Campbell IG.

Breast Cancer Res Treat. 2016 Sep;159(2):385-92. doi: 10.1007/s10549-016-3944-3. Epub 2016 Aug 20.

PMID:
27544226
14.

No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing.

Easton DF, Lesueur F, Decker B, Michailidou K, Li J, Allen J, Luccarini C, Pooley KA, Shah M, Bolla MK, Wang Q, Dennis J, Ahmad J, Thompson ER, Damiola F, Pertesi M, Voegele C, Mebirouk N, Robinot N, Durand G, Forey N, Luben RN, Ahmed S, Aittomäki K, Anton-Culver H, Arndt V; Australian Ovarian Cancer Study Group, Baynes C, Beckman MW, Benitez J, Van Den Berg D, Blot WJ, Bogdanova NV, Bojesen SE, Brenner H, Chang-Claude J, Chia KS, Choi JY, Conroy DM, Cox A, Cross SS, Czene K, Darabi H, Devilee P, Eriksson M, Fasching PA, Figueroa J, Flyger H, Fostira F, García-Closas M, Giles GG, Glendon G, González-Neira A, Guénel P, Haiman CA, Hall P, Hart SN, Hartman M, Hooning MJ, Hsiung CN, Ito H, Jakubowska A, James PA, John EM, Johnson N, Jones M, Kabisch M, Kang D; kConFab Investigators, Kosma VM, Kristensen V, Lambrechts D, Li N; Lifepool Investigators, Lindblom A, Long J, Lophatananon A, Lubinski J, Mannermaa A, Manoukian S, Margolin S, Matsuo K, Meindl A, Mitchell G, Muir K; NBCS Investigators, Nevelsteen I, van den Ouweland A, Peterlongo P, Phuah SY, Pylkäs K, Rowley SM, Sangrajrang S, Schmutzler RK, Shen CY, Shu XO, Southey MC, Surowy H, Swerdlow A, Teo SH, Tollenaar RA, Tomlinson I, Torres D, Truong T, Vachon C, Verhoef S, Wong-Brown M, Zheng W, Zheng Y, Nevanlinna H, Scott RJ, Andrulis IL, Wu AH, Hopper JL, Couch FJ, Winqvist R, Burwinkel B, Sawyer EJ, Schmidt MK, Rudolph A, Dörk T, Brauch H, Hamann U, Neuhausen SL, Milne RL, Fletcher O, Pharoah PD, Campbell IG, Dunning AM, Le Calvez-Kelm F, Goldgar DE, Tavtigian SV, Chenevix-Trench G.

J Med Genet. 2016 May;53(5):298-309. doi: 10.1136/jmedgenet-2015-103529. Epub 2016 Feb 26.

15.

Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.

Thompson ER, Rowley SM, Li N, McInerny S, Devereux L, Wong-Brown MW, Trainer AH, Mitchell G, Scott RJ, James PA, Campbell IG.

J Clin Oncol. 2016 May 1;34(13):1455-9. doi: 10.1200/JCO.2015.63.7454. Epub 2016 Jan 19.

PMID:
26786923
16.

Searching for candidate genes in familial BRCAX mutation carriers with prostate cancer.

Hunter SM, Rowley SM, Clouston D; KCon Fab Investigators, Li J, Lupat R, Krishnananthan N, Risbridger G, Taylor R, Bolton D, Campbell IG, Thorne H.

Urol Oncol. 2016 Mar;34(3):120.e9-16. doi: 10.1016/j.urolonc.2015.10.009. Epub 2015 Nov 14.

PMID:
26585945
17.

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.

Hunter SM, Anglesio MS, Ryland GL, Sharma R, Chiew YE, Rowley SM, Doyle MA, Li J, Gilks CB, Moss P, Allan PE, Stephens AN, Huntsman DG, deFazio A, Bowtell DD; Australian Ovarian Cancer Study Group, Gorringe KL, Campbell IG.

Oncotarget. 2015 Nov 10;6(35):37663-77. doi: 10.18632/oncotarget.5438.

18.

Reevaluation of the BRCA2 truncating allele c.9976A > T (p.Lys3326Ter) in a familial breast cancer context.

Thompson ER, Gorringe KL, Rowley SM, Li N, McInerny S, Wong-Brown MW, Devereux L, Li J; Lifepool Investigators, Trainer AH, Mitchell G, Scott RJ, James PA, Campbell IG.

Sci Rep. 2015 Oct 12;5:14800. doi: 10.1038/srep14800.

19.

Copy number analysis of ductal carcinoma in situ with and without recurrence.

Gorringe KL, Hunter SM, Pang JM, Opeskin K, Hill P, Rowley SM, Choong DY, Thompson ER, Dobrovic A, Fox SB, Mann GB, Campbell IG.

Mod Pathol. 2015 Sep;28(9):1174-84. doi: 10.1038/modpathol.2015.75. Epub 2015 Jun 19.

20.

Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls.

Thompson ER, Gorringe KL, Rowley SM, Wong-Brown MW, McInerny S, Li N, Trainer AH, Devereux L, Doyle MA, Li J, Lupat R, Delatycki MB; LifePool Investigators, Mitchell G, James PA, Scott RJ, Campbell IG.

Breast Cancer Res. 2015 Aug 19;17:111. doi: 10.1186/s13058-015-0627-7.

21.

Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors.

Ryland GL, Hunter SM, Doyle MA, Caramia F, Li J, Rowley SM, Christie M, Allan PE, Stephens AN, Bowtell DD; Australian Ovarian Cancer Study Group, Campbell IG, Gorringe KL.

Genome Med. 2015 Aug 7;7(1):87. doi: 10.1186/s13073-015-0210-y. eCollection 2015. Erratum in: Genome Med. 2017 Jan 12;9(1):1.

22.

Loss of heterozygosity: what is it good for?

Ryland GL, Doyle MA, Goode D, Boyle SE, Choong DY, Rowley SM, Li J; Australian Ovarian Cancer Study Group, Bowtell DD, Tothill RW, Campbell IG, Gorringe KL.

BMC Med Genomics. 2015 Aug 1;8:45. doi: 10.1186/s12920-015-0123-z.

23.

Tumor progression locus 2 (Tpl2) kinase promotes chemokine receptor expression and macrophage migration during acute inflammation.

Rowley SM, Kuriakose T, Dockery LM, Tran-Ngyuen T, Gingerich AD, Wei L, Watford WT.

J Biol Chem. 2014 May 30;289(22):15788-97. doi: 10.1074/jbc.M114.559344. Epub 2014 Apr 8.

24.

A simple consensus approach improves somatic mutation prediction accuracy.

Goode DL, Hunter SM, Doyle MA, Ma T, Rowley SM, Choong D, Ryland GL, Campbell IG.

Genome Med. 2013 Sep 30;5(9):90. doi: 10.1186/gm494. eCollection 2013.

25.

Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancer.

Thompson ER, Rowley SM, Sawyer S, kConfab, Eccles DM, Trainer AH, Mitchell G, James PA, Campbell IG.

PLoS One. 2013;8(1):e54772. doi: 10.1371/journal.pone.0054772. Epub 2013 Jan 25.

26.

RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary.

Ryland GL, Hunter SM, Doyle MA, Rowley SM, Christie M, Allan PE, Bowtell DD; Australian Ovarian Cancer Study Group, Gorringe KL, Campbell IG.

J Pathol. 2013 Feb;229(3):469-76. doi: 10.1002/path.4134.

PMID:
23096461
27.

Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles.

Thompson ER, Doyle MA, Ryland GL, Rowley SM, Choong DY, Tothill RW, Thorne H; kConFab, Barnes DR, Li J, Ellul J, Philip GK, Antill YC, James PA, Trainer AH, Mitchell G, Campbell IG.

PLoS Genet. 2012 Sep;8(9):e1002894. doi: 10.1371/journal.pgen.1002894. Epub 2012 Sep 27.

28.

Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations.

Hunter SM, Gorringe KL, Christie M, Rowley SM, Bowtell DD; Australian Ovarian Cancer Study Group, Campbell IG.

Clin Cancer Res. 2012 Oct 1;18(19):5267-77. doi: 10.1158/1078-0432.CCR-12-1103. Epub 2012 Aug 13.

29.

MicroRNA genes and their target 3'-untranslated regions are infrequently somatically mutated in ovarian cancers.

Ryland GL, Bearfoot JL, Doyle MA, Boyle SE, Choong DY, Rowley SM; Australian Ovarian Cancer Study Group, Tothill RW, Gorringe KL, Campbell IG.

PLoS One. 2012;7(4):e35805. doi: 10.1371/journal.pone.0035805. Epub 2012 Apr 20.

30.

FXN methylation predicts expression and clinical outcome in Friedreich ataxia.

Evans-Galea MV, Carrodus N, Rowley SM, Corben LA, Tai G, Saffery R, Galati JC, Wong NC, Craig JM, Lynch DR, Regner SR, Brocht AF, Perlman SL, Bushara KO, Gomez CM, Wilmot GR, Li L, Varley E, Delatycki MB, Sarsero JP.

Ann Neurol. 2012 Apr;71(4):487-97. doi: 10.1002/ana.22671.

PMID:
22522441
31.

Long range regulation of human FXN gene expression.

Puspasari N, Rowley SM, Gordon L, Lockhart PJ, Ioannou PA, Delatycki MB, Sarsero JP.

PLoS One. 2011;6(7):e22001. doi: 10.1371/journal.pone.0022001. Epub 2011 Jul 8.

32.

Detection of interruptions in the GAA trinucleotide repeat expansion in the FXN gene of Friedreich ataxia.

Holloway TP, Rowley SM, Delatycki MB, Sarsero JP.

Biotechniques. 2011 Mar;50(3):182-6. doi: 10.2144/000113615.

33.

Headaches in children and adolescents. A blueprint for pharmacologic and nonpharmacologic approaches.

Rowley SM.

Adv Nurse Pract. 2005 Feb;13(2):31-2, 34, 37-43. Review. No abstract available.

PMID:
15717674
34.

Wolbachia pipientis in Australian spiders.

Rowley SM, Raven RJ, McGraw EA.

Curr Microbiol. 2004 Sep;49(3):208-14.

PMID:
15386106
35.

Effectiveness of the electronic medical record in improving the management of hypertension.

Kinn JW, Marek JC, O'Toole MF, Rowley SM, Bufalino VJ.

J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):415-9.

36.

Effectiveness of the electronic medical record in cholesterol management in patients with coronary artery disease (Virtual Lipid Clinic).

Kinn JW, O'Toole MF, Rowley SM, Marek JC, Bufalino VJ, Brown AS.

Am J Cardiol. 2001 Jul 15;88(2):163-5, A5.

PMID:
11448414

Supplemental Content

Loading ...
Support Center